Patents Assigned to STEMBIOSYS, INC.
  • Amniotic fluid cell-derived extracellular matrix and uses thereof
    Patent number: 12270051
    Abstract: Disclosed is a cell-derived extracellular matrix (ECM) derived in vitro from cells isolated from amniotic fluid, and methods of use for the isolation, maintenance, and proliferation of adherent cells including stem cells, as well as for the differentiation of stem cells.
    Type: Grant
    Filed: October 13, 2021
    Date of Patent: April 8, 2025
    Assignee: STEMBIOSYS, INC.
    Inventors: Travis Block, Edward S. Griffey, Mary M. Navarro
  • AMNIOTIC FLUID CELL-DERIVED EXTRACELLULAR MATRIX AND USES THEREOF
    Publication number: 20250066732
    Abstract: Disclosed is a cell-derived extracellular matrix (ECM) derived in vitro from cells isolated from amniotic fluid, and methods of use for the isolation, maintenance, and proliferation of adherent cells including stem cells, as well as for the differentiation of stem cells.
    Type: Application
    Filed: November 14, 2024
    Publication date: February 27, 2025
    Applicant: STEMBIOSYS, INC.
    Inventors: Travis BLOCK, Edward S. GRIFFEY, Mary M. NAVARRO
  • METHODS FOR THE MATURATION OF CARDIOMYOCYTES ON AMNIOTIC FLUID CELL-DERIVED ECM, CELLULAR CONSTRUCTS, AND USES FOR CARDIOTOXICITY AND PROARRHYTHMIC SCREENING OF DRUG COMPOUNDS
    Publication number: 20220119770
    Abstract: Disclosed are methods of using a cell-derived extracellular matrix derived in-vitro from cells isolated from amniotic fluid (AFC-ECM) for the maturation of immature cardiomyocytes derived from human induced pluripotent stem cells (immature hiPSC-CMs) in culture forming mature cardiomyocytes. Also disclosed is a cell construct comprising a monolayer of these mature cardiomyocytes on an AFC-ECM useful for cardiotoxicity and/or proarrhythmic screening assays of drug compounds. Also disclosed are methods for determining the cardiotoxicity and/or proarrhythmic effect of a drug compound in vitro using such cell constructs.
    Type: Application
    Filed: November 19, 2021
    Publication date: April 21, 2022
    Applicant: STEMBIOSYS, INC.
    Inventors: Travis BLOCK, Edward S. GRIFFEY, Todd HERRON
  • Methods for the maturation of cardiomyocytes on amniotic fluid cell-derived ECM, cellular constructs, and uses for cardiotoxicity and proarrhythmic screening of drug compounds
    Patent number: 11220671
    Abstract: Disclosed herein are methods of using a cell-derived extracellular matrix derived in-vitro from cells isolated from amniotic fluid (AFC-ECM) for the maturation of immature cardiomyocytes derived from human induced pluripotent stem cells (immature hiPSC-CMs) in culture forming mature cardiomyocytes. Also disclosed herein is a cell construct comprising a monolayer of these mature cardiomyocytes on an AFC-ECM useful for cardiotoxicity and/or proarrhythmic screening assays of drug compounds. Also disclosed herein are methods for determining the cardiotoxicity and/or proarrhythmic effect of a drug compound in vitro using such cell constructs.
    Type: Grant
    Filed: February 21, 2020
    Date of Patent: January 11, 2022
    Assignee: STEMBIOSYS, INC.
    Inventors: Travis Block, Edward S. Griffey, Todd Herron
  • Amniotic fluid cell-derived extracellular matrix and uses thereof
    Patent number: 11180732
    Abstract: Disclosed is a cell-derived extracellular matrix (ECM) derived in vitro from cells isolated from amniotic fluid, and methods of use for the isolation, maintenance, and proliferation of adherent cells including stem cells, as well as for the differentiation of stem cells.
    Type: Grant
    Filed: October 3, 2019
    Date of Patent: November 23, 2021
    Assignee: STEMBIOSYS, INC.
    Inventors: Travis Block, Edward S. Griffey, Mary Navarro
  • BONE MARROW STROMAL CELL DERIVED EXTRACELLULAR MATRIX PROTEIN EXTRACT AND USES THEREOF
    Publication number: 20180200302
    Abstract: Disclosed are bone marrow stromal cell derived extracellular matrix protein extracts that are useful for the expansion and proliferation of mesenchymal stem cells and for various therapeutic applications.
    Type: Application
    Filed: March 13, 2018
    Publication date: July 19, 2018
    Applicant: STEMBIOSYS, INC.
    Inventors: Rogelio ZAMILPA, Edward S. Griffey